Sangamo Therapeutics (SGMO) Stock Price, News & Analysis

Company Overview

Sangamo Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing genomic medicines for serious diseases. The company’s platform is based on zinc finger proteins, which it uses to design gene-editing nucleases, gene-regulation technologies and cell therapies intended to modify disease-related genetic activity.

Sangamo has developed investigational programs in areas including genetic, neurological and immune-mediated diseases. Its pipeline has included ST-920, an experimental gene therapy for Fabry disease, as well as programs using gene regulation and cell engineering approaches. These candidates remain subject to clinical testing and regulatory review, and the company does not currently market an approved product.

Founded in 1995, Sangamo is headquartered in Brisbane, California. The company has advanced its programs through internal research and collaborations with larger pharmaceutical and biotechnology organizations, supporting development efforts for patients in the United States and international markets. Sandy Macrae has served as the company’s chief executive officer since 2016.

Key Stats

• Today's Range: $0.07 to $0.07
• 50-Day Range: $0.07 to $0.07
• 52-Week Range: $0.06 to $0.77
• Volume: N/A
• Average Volume: 8.10 million shs
• Market Capitalization: $30.66 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $5.50
• Consensus Rating: Reduce

Sangamo Therapeutics Stock Analysis - MarketRank™

Sangamo Therapeutics scored higher than 20% of companies evaluated by MarketBeat, and ranked 814th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.9 / 5
• Analyst Rating: Reduce

Consensus Rating

Sangamo Therapeutics has received a consensus rating of Reduce. The company's average rating score is 1.75, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and 2 sell ratings.

Upside Potential

Sangamo Therapeutics has a consensus price target of $5.50, representing about 7,332.4% upside from its current price of $0.07.

Amount of Analyst Coverage

Sangamo Therapeutics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Sangamo Therapeutics is -0.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Sangamo Therapeutics is -0.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for SGMO.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Sangamo Therapeutics does not currently pay a dividend.

Dividend Growth

Sangamo Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

2 people have searched for SGMO on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Sangamo Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Sangamo Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

4.10% of the stock of Sangamo Therapeutics is held by insiders.

Percentage Held by Institutions

56.92% of the stock of Sangamo Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 11/06/2025
• Today: 9/19/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:SGMO
• CIK: 1001233
• Web: www.sangamo.com
• Phone: (510) 970-6000
• Fax: 510-236-8951
• Employees: 480
• Year Founded: 1995

Price Target and Rating

• Average Price Target for Sangamo Therapeutics: $5.50
• High Price Target: $10.00
• Low Price Target: $1.00
• Potential Upside/Downside: +7,332.4%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.75
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.38)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$122.93 million
• Net Margins: -310.81%
• Pretax Margin: -312.25%
• Return on Equity: -2,662.06%
• Return on Assets: -132.12%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.84
• Quick Ratio: 0.84

Sales & Book Value

• Annual Sales: $39.55 million
• Price / Sales: 0.78
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.04) per share
• Price / Book: -1.85

Miscellaneous

• Outstanding Shares: 414,289,000
• Free Float: 397,291,000
• Market Cap: $30.66 million
• Optionable: Optionable
• Beta: 1.30